Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.65 |
| ▸ | ATM | Q13315 | 2/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | PPARG | P37231 | 1/20 | 0.61 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5774873 | 0.90 | LMNA (0.54) | LMNASMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL316185 | 0.90 | ALDH1A1 (0.76) | LMNASMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL10520781 | 0.89 | LMNA (0.68) | LMNASMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL30881266 | 0.89 | LMNA (0.68) | LMNASMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL1065677 | 0.89 | LMNA (0.68) | LMNASMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL7184918 | 0.88 | TSHR (0.82) | LMNASMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL10332625 | 0.88 | LMNA (0.67) | LMNASMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL5774615 | 0.87 | LMNA (0.59) | LMNASMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL12457296 | 0.86 | TSHR (0.69) | LMNASMN1; SMN2KMT2AALDH1A1GPBAR1 | |
| SCHEMBL11893412 | 0.85 | ALDH1A1 (0.72) | LMNASMN1; SMN2KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115677607-B | Isoxazole amide derivative and preparation method and application thereof | 遵义医科大学 | 2023-10-31 | — | — | CN | claimed |
| CN-115677607-A | Isoxazole amide derivative and preparation method and application thereof | 遵义医科大学 | 2023-02-03 | — | — | CN | claimed |
| CN-109400630-B | Synthetic method of flucloxacillin sodium | 浙江普洛得邦制药有限公司 | 2021-07-02 | — | — | CN | claimed |
| CN-102964356-A | Synthesis method of flucloxacillin sodium | HEZE RUIZHI TECHNOLOGY DEV CO LTD | 2013-03-13 | — | — | CN | claimed |
| EP-1745009-B1 | HETEROARYL SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2012-11-14 | — | — | EP | claimed |
| CN-100467455-C | Synthetic method for 3-(2'-chloro-6'-fluorophenyl)-5-methyl-4-isooxazole formyl chloride | UNIV ZHEJIANG TECHNOLOGY (CN) | 2009-03-11 | — | — | CN | claimed |
| JP-2007536321-A | — | — | 2007-12-13 | — | — | JP | claimed |
| CN-101016272-A | Synthetic method for 3-(2'-chloro-6'-fluorophenyl)-5-methyl-4-isooxazole formyl chloride | UNIV ZHEJIANG TECHNOLOGY (CN) | 2007-08-15 | — | — | CN | claimed |
| US-20070129369-A1 | Heteroaryl substituted cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-06-07 | — | — | US | claimed |
| EP-1745009-A1 | HETEROARYL SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES | Grünenthal GmbH (DE) | 2007-01-24 | — | — | EP | claimed |
| WO-2005110971-A1 | HETEROARYL SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES | Grünenthal GmbH (DE) | 2005-11-24 | — | — | WO | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| EP-1250340-B1 | METHODS AND COMPOUNDS FOR INHIBITING MRP1 | LILLY CO ELI (US) | 2004-11-17 | — | — | EP | claimed |
| US-20250346575-A1 | ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-11-13 | — | — | US | disclosed |
| EP-4431505-A1 | ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF | Korea Research Institute of Chemical Technology (KR) | 2024-09-18 | — | — | EP | disclosed |
| CN-118234721-A | Isoindolinone derivative with glutarimide mother nucleus and application thereof | 韩国化学研究院 | 2024-06-21 | — | — | CN | disclosed |
| WO-1997005131-A1 | NEW CARBOXAMIDES WITH ANTIFUNGAL ACTIVITY | J. URIACH & CIA. S.A. (ES) | 1997-02-13 | — | — | WO | disclosed |
| CN-1033031-C | Modified gangliosides and functional derivatives thereof | FIDIA SPA (IT) | 1996-10-16 | — | — | CN | disclosed |
| CN-1051912-A | Improved gangliosides and functional derivatives thereof | FIDIA B P A (IT) | 1991-06-05 | — | — | CN | disclosed |
| US-4230849-A | Process for the activation of carboxylic acids | ANTIBIOTICOS, S.A. (ES) | 1980-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129369-A1 | Heteroaryl substituted cyclohexyl-1,4-diamine compounds | DDC, DPYD, PKD1 | LMNA 2080/4885SMN1; SMN2 1685/4885KMT2A 3031/4885 |
| US-20250346575-A1 | ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF | CRBN, IDH1, IDH2 | LMNA 2564/4885SMN1; SMN2 2400/4885KMT2A 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.